Bruker cuts 2025 guidance and expands cost savings after Q2 revenue slips 0.4%
Bruker reported second quarter 2025 revenue of $797.4 million, down 0.4% from a year earlier, and non-GAAP diluted EPS of $0.32, down 38.5%. The company lowered its FY 2025 non-GAAP EPS guidance to $1.95 to $2.05 from the prior range implied by its outlook, citing weak demand in academic, biopharma and industrial markets, plus tariffs and currency pressure. Shareholders face lower near-term profit expectations, partly offset by a planned cost program of $100 million to $120 million in annual savings for FY 2026.
Key points
- Q2 2025 revenue $797.4 million, down 0.4% yoy; organic revenue down 7.0%
- Q2 2025 non-GAAP diluted EPS $0.32 vs. $0.52 a year earlier; GAAP diluted EPS $0.05
- FY 2025 guidance: revenue $3.43 to $3.50 billion and non-GAAP EPS $1.95 to $2.05, compared with $2.41 in FY 2024
- Cost savings initiative expected to reduce annual costs by $100 million to $120 million in FY 2026
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.